Evidence map›Paper›PMID 41227304›Full record

ReviewCells2025

Study Models for Non-Syndromic Hearing Loss.

Valentine Hoyau, Jean-Christophe Leclère, Stéphanie Moisan

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Valentine HoyauUniv. Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France.ORCID 0009-0009-8508-7013
Jean-Christophe LeclèreDépartement D'oto-Rhino-Laryngologie et de Chirurgie Cervico-Faciale, CHU Brest, Univ. Brest, EA4685, LIEN, F-29200 Brest, France.
Stéphanie MoisanLaboratoire de Génétique Moléculaire et d'Histocompatibilité, CHU Brest, Univ. Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hearing loss is the most common sensory disorder; It is estimated that nearly 2.5 billion people will have some degree of hearing loss by 2050. Although the causes are diverse, a significant proportion of cases have a genetic origin, which is the main focus of the models discussed in this review. Many loci corresponding to deafness genes have already been identified, and approximately 150 genes are responsible for non-syndromic deafness, which is characterized by partial or total hearing loss that is not associated with other signs or symptoms. Although hearing aids and cochlear implants are widely available today, their effectiveness is often limited, especially in noisy environments, prompting the development of advanced therapies for hearing loss. To evaluate new therapies and improve our understanding of hearing physiology, various models, including cellular, animal, and organoid models, are used to study the inner ear. In this review, we present these different models in detail, with their respective strengths and limitations. This analysis will be particularly valuable in helping researchers to identify the most appropriate model for their specific research questions and to justify their choices from an ethical perspective.

Indexed as

Hearing LossModels, BiologicalAnimalsDisease Models, AnimalHumansanimalscell linesgenetichearing lossmodelsorganoids

Identifiers

PMID41227304
PMCPMC12608605

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.